Setback for prostate cancer pill

teaser

Plans to launch an experimental prostate cancer pill have been put onhold after it failed to improve survival rates in a late-stage clinicaltrial.

Biopharmaceutical company AstraZeneca will now go back to the drawingboard and plans no regulatory submissions for zibotentan after testingrevealed that it failed to improve overall survival rates in the PhaseIII study.

This latest setback comes after similarly unsuccessful trials for twoother AstraZeneca pills – Recentin in colon cancer earlier this yearand vandetanib in lung cancer in 2009.

↓Article continues below this sponsored advert↓

Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.

Agenda Register

↑Advertisement↑

Zibotentan, a once-daily tablet, is being studied in more than 3,000men with prostate cancer in a programme of clinical trials, while twoother studies which are exploring other potential uses for the drug arestill ongoing.

Trial results